APA (7th ed.) Citation

BA, C., KP, P., JH, S., AB, L., SN, W., YK, C., . . . HK, G. (2022). Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neuro-oncology advances, 5(1), vdac183. https://doi.org/10.1093/noajnl/vdac183

Chicago Style (17th ed.) Citation

BA, Carneiro, et al. "Phase I Study of Anti-epidermal Growth Factor Receptor Antibody-drug Conjugate Serclutamab Talirine: Safety, Pharmacokinetics, and Antitumor Activity in Advanced Glioblastoma." Neuro-oncology Advances 5, no. 1 (2022): vdac183. https://doi.org/10.1093/noajnl/vdac183.

MLA (9th ed.) Citation

BA, Carneiro, et al. "Phase I Study of Anti-epidermal Growth Factor Receptor Antibody-drug Conjugate Serclutamab Talirine: Safety, Pharmacokinetics, and Antitumor Activity in Advanced Glioblastoma." Neuro-oncology Advances, vol. 5, no. 1, 2022, p. vdac183, https://doi.org/10.1093/noajnl/vdac183.